The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 13, 2021

Filed:

Nov. 20, 2015
Applicant:

Umc Utrecht Holding B.v., Utrecht, NL;

Inventor:
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); A61K 35/17 (2015.01); G01N 33/569 (2006.01); C07K 14/725 (2006.01);
U.S. Cl.
CPC ...
A61K 39/001102 (2018.08); A61K 35/17 (2013.01); A61K 39/0011 (2013.01); C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); C12N 5/0636 (2013.01); G01N 33/56972 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); C07K 2317/73 (2013.01); C12N 2501/515 (2013.01); C12N 2510/00 (2013.01);
Abstract

The current application provides for exogenous immune receptors that do not require any additional selection marker genes and/or any additional silicide genes. The disclosure allows for the production of engineered T cells that can be enriched for in an untouched manner, i.e., the engineered T cells do not require any interaction with any outside agent and can be selected for by eliminating T cells that express the endogenous alpha beta T cell receptor. Engineered T cells with an exogenous immune receptor are provided that can be differentiated from endogenous T cell receptor and now can be eliminated, i.e., depleted, with a selective antibody that specifically targets the exogenous immune receptor.


Find Patent Forward Citations

Loading…